๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

23 recruiting trials

for Beta Thalassemia Transfusion Dependent

Long-term Follow-up Study of BHC001 for TDT NCT06314529n/a2 sites๐Ÿ“ Nanning๐Ÿ“ Changsha Bioray Laboratories ยท Tests: Assessments A Trial Testing SP-420 in Subjects With Transfusion-dependent ฮฒ-thalassemia or Low-risk Myelodysplastic Syndromes NCT05693909Phase 21 site๐Ÿ“ Copenhagen Pharmacosmos A/S ยท Tests: SP-420 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias NCT03653338Phase 1, Phase 21 site๐Ÿ“ Pittsburgh Paul Szabolcs ยท Tests: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia NCT07680803Phase 22 sites๐Ÿ“ Rome๐Ÿ“ Milan Fondazione Telethon ยท Tests: FT007 A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent ฮฒ-Thalassemia [TDT] NCT05762510EARLY Phase 11 site๐Ÿ“ Nanning First Affiliated Hospital of Guangxi Medical University ยท Tests: GMCN-508B (LentiRed) Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia NCT06490627Phase 21 site๐Ÿ“ Karachi National Institute of Blood and Marrow Transplant (NIBMT), โ€ฆ ยท Tests: Thalidomide, Thalidomide Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent ฮฒ-Thalassemia and Severe Sickle Cell Disease NCT05477563Phase 36 sites๐Ÿ“ New York๐Ÿ“ Charlotte๐Ÿ“ Nashville Vertex Pharmaceuticals Incorporated ยท Tests: CTX001 Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia NCT05773729NA1 site๐Ÿ“ Shanghai Shanghai BDgene Co., Ltd. ยท Tests: BD211 Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients NCT06219239NA1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: KL003 cell injection Drug Product A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent ฮฒ-thalassemia NCT06772766Phase 12 sites๐Ÿ“ Nanning๐Ÿ“ Haikou Mabwell (Shanghai) Bioscience Co., Ltd. ยท Tests: 9MW3011, 9MW3011 placebo ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia NCT06364774Phase 1, Phase 21 site๐Ÿ“ Philadelphia Children's Hospital of Philadelphia ยท Tests: ALS20 Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent ฮฒ-Thalassemia NCT07884773Phase 31 site๐Ÿ“ Peshawar Khyber Medical University Peshawar ยท Tests: Thalidomide, Danazol, Prednisolone Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent ฮฒ-thalassemia NCT05776173NA1 site๐Ÿ“ Shanghai Shanghai BDgene Co., Ltd. ยท Tests: BD211 A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (ฮฑ- or ฮฒ-TDT) NCT07506863Phase 34 sites๐Ÿ“ Atlanta๐Ÿ“ New York๐Ÿ“ Philadelphia Agios Pharmaceuticals, Inc. ยท Tests: Mitapivat Matched Placebo, Mitapivat ฮ’-Thalassemia Treatment with KL003 Cell Injection NCT06280378Phase 1, Phase 22 sites๐Ÿ“ Shanghai๐Ÿ“ Tianjin Kanglin Biotechnology (Hangzhou) Co., Ltd. ยท Tests: KL003 Cell Injection Drug Product Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy NCT05991336n/a1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Gene therapy Long-term Follow-up Study of BRL-101 for TDT NCT06298630n/a7 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou๐Ÿ“ Shenzhen Bioray Laboratories ยท Tests: Assessments A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With ฮฑ- or ฮฒ-Non-Transfusion-Dependent Thalassemia NCT07517133Phase 35 sites๐Ÿ“ Palo Alto๐Ÿ“ Atlanta๐Ÿ“ New York Agios Pharmaceuticals, Inc. ยท Tests: Mitapivat, Placebo Matching Mitapivat Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site๐Ÿ“ Pittsburgh Paul Szabolcs ยท Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East NCT07215975n/a13 sites๐Ÿ“ Al Jahra๐Ÿ“ Andalusia๐Ÿ“ Kuwait City Bristol-Myers Squibb ยท Tests: Luspatercept Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe ฮฒ-Hemoglobinopathies NCT06647979Phase 11 site๐Ÿ“ Boston Daniel Bauer ยท Tests: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequenโ€ฆ Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With ฮฒ-TTD NCT07207577NA1 site๐Ÿ“ Chambรฉry Centre Hospitalier Metropole Savoie ยท Tests: Maximal incremental exercise test A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating ฮฒ-thalassemia Major NCT06465550Phase 13 sites๐Ÿ“ Guangzhou๐Ÿ“ Nanning๐Ÿ“ Shanghai Shanghai BDgene Co., Ltd. ยท Tests: BD211
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy